SR 1375
Alternative Names: SR-1375Latest Information Update: 28 Oct 2024
At a glance
- Originator SIMR Biotech
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Community-acquired pneumonia; Diabetic macular oedema
- Preclinical Inflammation
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Diabetic-macular-oedema(In volunteers) in Australia (PO, Capsule)
- 10 Sep 2024 Phase-II clinical trials in Community-acquired pneumonia in China (PO) (NCT06577558),
- 07 Sep 2024 Adverse events and efficacy data from a phase-II trial in Community-acquired Pneumonia presented at the 34th Annual Congress of the European Respiratory Society (ERS-2024)